Universal leukocyte reduction

Current Opinion in Hematology

Volumn 7, Issue 6, 2000, Pages 397-401

  Kopko, Patricia M ^a   Holland, Paul V ^a  

^a Sacramento Medical Foundation Blood Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD COMPONENT; BLOOD TRANSFUSION; BLOOD TRANSFUSION REACTION; CREUTZFELDT JAKOB DISEASE; DISEASE TRANSMISSION; HEALTH CARE COST; IMMUNOMODULATION; LEUKOPENIA; PRIORITY JOURNAL; REVIEW; SICKLE CELL TRAIT; TREATMENT OUTCOME;

BLOOD COMPONENT REMOVAL; CREUTZFELDT-JAKOB SYNDROME; HUMANS; LEUKOCYTES;

EID: 0033785245     PISSN: 10656251     EISSN: None     Source Type: Journal    
DOI: 10.1097/00062752-200011000-00013     Document Type: Review

References (37)

1. Leukocyte reduction and ultraviolet B irradiation of platelets to prevent alloimmunization and refractoriness to platelet transfusions
2. A comparison of filtered leukocyte-reduced and cytomegalovirus (CMV) seronegative blood products for the prevention of transfusion-associated CMV infection after marrow transplant
3. Blood Products Advisory Committee recommends universal leukoreduction of blood components
4. The relationship between new variant Creutzfeldt·Jakob disease and bovine spongiform encephalopathy
5. The possible relationship between BSE and use of pituitary hormones in cows
6. Oxytocin (pituitary posterior lobe extract): Another potential route of BCE infection in the livestock herd
7. A new variant of Creutzfeldt-Jakob disease in the UK
8. The distribution of infectivity in blood components and plasma derivatives in experimental models of transmissible spongiform encephalopathy
9. The risk of blood-borne Creutzfeldt-Jakob disease
10. Further studies of blood infectivity in an experimental model of transmissible spongiform encephalopathy, with an explanation of why blood components do not transmit Creutzfeldt-Jakob disease in humans
11. Surveillance for Creutzfeldt-Jakob disease among persons with hemophilia
12. A crucial role for B cells in neuroinvasive scrapie
13. Investigation of variant Creutzfeldt-Jakob disease and other human prion diseases with tonsil biopsy samples
14. Impaired prion replication in spleens of mice lacking functional follicular dendritic cells
15. New variant Creutzfeldt-Jakob disease and white cell reduction: Risk assessment and decision making in the absence of data
16. Ineffective prestorage leukoreduction (PSLR) of whole blood (WB) from African-American donors with sickle cell trait (HB AS) versus controls
17. Leukocyte depletion of whole blood and red cells from donors with hemoglobin sickle trait
18. Leukocyte reduction of blood components: Public policy and new technology
19. A framework for measuring the economic benefits of universal leukoreduction
20. Impact of leukoreduced red blood cells (LR RBC) on length of stay (LOS) in surgical patients cost-justifies universal leukocyte reduction
21. Effect of blood transfusions on subsequent kidney transplants
22. Blood transfusions in liver recipients. A conundrum or a clear benefit in the cyclosporine/tacrolimus era?
23. Transfusion-associated immunomodulation and universal white cell reduction: Are we putting the cart before the horse?
24. Leukocyte-reduction of red blood cells (RBC) does not improve clinical outcome in anemic patients with advanced HIV infection needing RBC transfusion
25. Supplemental perioperative oxygen to reduce the incidence of surgical-wound infection
26. A multicenter, randomized, controlled clinical trial of transfusion requirements in critical care
27. Where next with stem-cell-supported high-dose therapy for breast cancer?
28. Survival of donor leukocyte subpopulations in immunocompetent transfusion recipients: Frequent long-term microchimerism in severe trauma patients
29. Immune response to blood transfusion in very-low-birthweight infants
30. Reduction of bioactive substances in stored donor blood: Prestorage versus bedside leucofiltration
31. Benefit of prestorage leukocyte depletion of single-donor platelet concentrates
32. A randomized controlled trial comparing plasma removal with white cell reduction to prevent reactions to platelets
33. Effects of filtration and gamma radiation on the accumulation of RANTES and transforming growth factor-β1 in apheresis platelet concentrates during storage
34. Association between angiotensin-converting enzyme (ACE) inhibitors and hypotensive transfusion reactions
35. Adverse ocular reactions following transfusions-United States, 1997-1998
36. American Red Cross suspends use of HemaSure blood filtration system to investigate adverse patient reactions